Braveheart Bio, Inc. BRVE
IPO
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 15.04% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 5.54% | ||||
| Operating Income | -5.54% | ||||
| Income Before Tax | -4.96% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -4.96% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -4.96% | ||||
| EBIT | -5.54% | ||||
| EBITDA | -5.53% | ||||
| EPS Basic | -20.79% | ||||
| Normalized Basic EPS | 2.68% | ||||
| EPS Diluted | -20.79% | ||||
| Normalized Diluted EPS | 2.68% | ||||
| Average Basic Shares Outstanding | 7.85% | ||||
| Average Diluted Shares Outstanding | 7.85% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||